NCT01679028View on ClinicalTrials.gov

Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

February 28, 2013

Conditions
Healthy
Interventions
DRUG

T89 Group A

150mg single dose on day 1

DRUG

Placebo Group A

150mg single dose

DRUG

Placebo Group B

300mg single dose

DRUG

T89 Group B

300mg single dose

DRUG

Placebo Group C

225mg bid

DRUG

T89 Group C

225mg bid

Trial Locations (1)

91206

California Clinical Trial Medical Group, Glendale

Sponsors

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

Tasly Pharmaceuticals, Inc.

INDUSTRY